ROS1 and cancer: Using multiomic analysis, Li Gao et al., showed that certain alterations such as ROS1 (c-ros oncogene 1), SPEN (spen family transcription repressor), and PTPRT (Protein Tyrosine Phosphatase Receptor Type T) were predictive of a response to immunotherapy across several cancer types.